BACKGROUND & AIMS: Sorafenib is the standard of care for the treatment of advanced
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …

Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …

Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). Some
patients with HCC initially respond to sorafenib, but eventually succumb to the disease …

Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma;
vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit …

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a particularly vascularized solid
tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this …

Abstract Background & Aims The study aimed to evaluate the tissue expression of molecules
involved in intracellular signalling pathways as predictors of response to sorafenib in …

Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven
efficacy against Hepatocellular Carcinoma (HCC). Although the overall clinical efficacy of …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Sorafenib is the first and only po administrated drug currently approved to treat advanced
hepatocellular carcinoma (HCC). However, concerns have been raised about sorafenib …

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide,
and prognosis remains unsatisfactory when the disease is diagnosed at an advanced stage …